BioCentury | Jun 23, 2020
Distillery Therapeutics

Blocking cGAS signaling for alcohol-related liver disease

DISEASE CATEGORY: Hepatic INDICATION: Liver disease Targeting the cGAS-IRF3 signaling pathway by inhibiting cGAS or the gap junction protein GJB1 could treat alcohol-related liver disease. In liver samples from alcoholic-related liver disease patients, high cGAS...
BioCentury | Oct 1, 2019
Company News

Oct. 1 Company Quick Takes: NVS, Microsoft to use AI for drug R&D; plus AstraZeneca, Tmunity-CHOP and AGTC-Otonomy deals

...therapy to restore hearing in patients with congenital hearing loss caused by a mutation in GJB2...
...development costs and profits, and may collaborate on future targets for congenital deafness. Targets: GJB2 (Connexin-26...
BioCentury | Apr 7, 2016
Distillery Therapeutics

Therapeutics: Gap junction protein β1, 32kDa (GJB1; CX32; connexin-32)

Neurology INDICATION: Neuropathy Mouse studies suggest GJB1 could help treat Charcot-Marie-Tooth type 1X (CMT1X), a disease caused by GJB1 mutations. In a GJB1-knockout mouse model of CMT1X, intrathecal injection of a viral vector encoding GJB1...
BioCentury | Feb 2, 2012
Distillery Therapeutics

Indication: Hepatic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Hepatic disease Drug-induced liver toxicity (DILI) Gap junction protein b1, 32 kDa (GJB1; CX32; connexin-32) Mouse studies identified a small molecule inhibitor of CX32 that could...
BioCentury | Feb 2, 2012
Targets & Mechanisms

Closing the gap on liver toxicity

...2APB inhibited CX32 and gap junction protein b2, 26 kDa ( GJB2 ; connexin-26 ; CX26...
BioCentury | Feb 2, 2012
Distillery Therapeutics

Indication

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Bladder cancer Keratin 14 (KRT14) Patient sample studies suggest KRT14 could help predict bladder cancer prognosis. In two sets of gene and protein expression data...
BioCentury | Dec 16, 2010
Distillery Therapeutics

Indication: Autoimmune disease

...gene 1 (PTTG1); CUB and sushi multiple domains 1 (CSMD1); gap junction protein b2, 26kDa (GJB2...
...arthritis. The final study included psoriasis patients from China and showed that ERAP1, PTTG1, CSMD1, GJB2...
BioCentury | May 3, 2004
Company News

Innogenetics NV, Third Wave sales and marketing update

INNX became the exclusive European distributor for TWTI's Invader molecular diagnostic products for genetic testing of certain risk factors for cardiovascular and hearing disorders, including Factor II (prothrombin), Factor V (Leiden), and Connexin 26. Under...
BioCentury | Apr 27, 2004
Company News

Innogenetics, Third Wave distribution deal

Innogenetics (Euronext:INNX) became the exclusive European distributor for TWTI's Invader molecular diagnostic products for genetic testing of certain risk factors for cardiovascular and hearing disorders, including Factor V (Leiden), Factor II (prothrombin), and Connexin 26....
BioCentury | Nov 3, 2003
Company News

Nanogen, Institute Pasteur deal

...Pasteur granted NGEN exclusive European rights to IP covering the detection of mutations in the GJB2...
Items per page:
1 - 10 of 11